Besides, it has been reported that overexpression of Aurora-A protein, a mitotic serine threonine kinase, plays a vital role in DOXO insensitivity in breast cancer cells which is mediated via upregulation of Akt-NF-κB signaling axis, triggering drug efflux pump, ABCG2, and Pgp1, and ultimately reduce DOXO accumulation in resistant cells [76,77]. Here, NFKB1 is linked to breast cancer.